Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is clearly titled “분기보고서” (Quarterly Report) covering the first quarter of fiscal year 11 (2026-01-01 to 2026-03-31). It contains extensive company overview, consolidated subsidiaries, capital changes, share structure, history, and likely includes detailed financial statements (full-length at 321,771 characters). This is not a mere announcement but the full interim/quarterly financial report itself. Therefore, it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 92% confidence The document is the Korean ‘주식등의 대량보유상황보고서(일반)’, a detailed filing disclosing a major shareholder’s changes in large shareholdings and reasons (e.g., contracts, option exercises, executive departures). This is a threshold-crossing beneficial ownership disclosure, matching the Major Shareholding Notification category (Code: MRQ).
2026-04-24 Korean
기업설명회(IR)개최
Investor Presentation Classification · 75% confidence The document is an announcement of a corporate Investor Relations event (Non-Deal Roadshow) detailing date, time, venue, participants, purpose, and IR materials publication. It is not a report itself but rather an investor presentation event notice, fitting the Investor Presentation category.
2026-04-03 Korean
기업설명회(IR)개최
Investor Presentation Classification · 90% confidence The document is an announcement (in Korean) of a corporate investor-relations event titled “기업설명회(IR) 개최” (an IR roadshow/presentation), listing date, venue, target audience, purpose, method (Non-Deal Roadshow), sponsors, posting of IR materials, and contact details. This fits the definition of an Investor Presentation (IP) rather than a financial report or other category.
2026-04-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 97% confidence The document is a formal announcement of the results of the company’s Annual General Meeting held on 2026-03-26, listing approved agenda items, voting percentages, board member reappointments, and related disclosures. It is a declaration of voting results rather than the meeting materials themselves or a full financial report. This matches the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from TiumBio. It provides the auditor's opinion (적정/Unqualified), financial highlights (assets, liabilities, equity, profit/loss), and specific regulatory disclosures required by the Korea Exchange (KRX) upon the completion of an audit. While it contains financial data, it is a standardized regulatory disclosure form announcing the receipt and filing of the audit report rather than the full, multi-page annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2025
2026-03-18 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.